Measles Virus-Infected Stem Cells for Ovarian Cancer

This trial tests a new approach for treating ovarian cancer that has returned after previous treatments. It uses MV-NIS infected mesenchymal stem cells, a special virus-infected stem cell, to target and kill cancer cells. The trial aims to find the safest dose and evaluate the method's effectiveness. Suitable participants have recurrent ovarian, primary peritoneal, or fallopian tube cancer and have already received specific chemotherapy drugs. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial does not specify if you need to stop taking your current medications, but it does exclude those on certain treatments like chemotherapy, immunotherapy, or biologic therapy within a few weeks before joining. It's best to discuss your specific medications with the trial team.

Research has shown that special stem cells, called MV-NIS infected mesenchymal stem cells, can help fight cancer by delivering substances that kill tumors. Early studies found that these cells can slow tumor growth. In past trials, patients generally tolerated the treatment well, with few serious side effects. Some minor side effects occurred but were usually manageable. It is important to note that this is an early-stage study, so while the results are promising, more research is needed to fully understand the treatment's safety and effectiveness.¹²³⁴⁵

Unlike the standard treatments for ovarian cancer, which typically involve surgery and chemotherapy, MV-NIS infected mesenchymal stem cells offer a novel approach by using a genetically modified measles virus. This treatment is unique because it employs an oncolytic virus that specifically targets and kills cancer cells while sparing healthy ones. Additionally, the inclusion of the thyroidal sodium iodide symporter (NIS) allows for enhanced imaging and tracking of the treatment's progress. Researchers are excited about this approach because it not only provides a targeted attack on cancer cells but also offers a potential new way to monitor and adjust treatment in real-time.

Research shows that a new treatment using MV-NIS infected mesenchymal stem cells may help fight ovarian cancer. In animal studies, these stem cells carried a modified measles virus directly to cancer cells, significantly reducing tumors. This method outperformed using the virus alone, particularly in animals already immune to measles. The stem cells act as delivery vehicles, helping the virus target and destroy cancer cells more effectively. Early results are promising, suggesting this approach could offer new hope for patients with recurring ovarian, primary peritoneal, or fallopian tube cancer.¹²³⁴⁶